Roquefort Therapeutics is headquartered in London and is publicly traded on the London Stock Exchange (LSE:ROQ) and the OTC Markets in the US (OTCQB: ROQAF)
Roquefort Therapeutics is a material biotech company focused on developing first in class, next generation medicines in the high value and high growth immuno-oncology market prior to partnering or selling to big pharma.
The Company has partnered with leading academic cancer research centres which complements our own world-class in-house expertise and laboratory infrastructure.
We are well positioned with five pre-clinical drug development programs, and have the foundation and team to deliver the key R&D and commercial milestones that will drive shareholder value.
